RELATED STUDY
Key Findings:
Type of Study:
Study Result: Inconclusive
Research Location(s):
Year of Pub:
Cannabinoids Studied:
Chemotype:
Terpenes Studied:
Receptors Studied:
Ligands Studied:
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: No effective dose
Route of Administration:
Cannabinoid Ratio: (CBD : THC) 0 : 0 
Dosing Regimen: Crohn's Disease: 115 mg THC or 10 mg CBD twice a day Ulcerative Colitis: 50 - 250 mg of CBD or 23 mg THC per day
Clinical Relevance: Cannabis for medicinal use in irritable bowel disease (IBD) is still questionable
Citation:
